Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01127438 · ClinicalTrials.gov registry record · Phase 4

A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations

A Phase 4 study, sponsored by Eisai.

Completed
Registry status
Phase 4
Development phase
153
Enrollment target

NCT01127438 is a Phase 4 study that has completed, run by Eisai. The registered enrollment target is 153 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01127438, a Phase 4 study, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 4
Development phase
153 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and efficacy of LUSEDRA (fospropofol disodium) and to determine whether a dose lower than currently approved can provide effective moderate sedation required to complete diagnostic or therapeutic procedures.

Interventions

  • DRUG fospropofol disodium Subgroup 1 Lower Dose
  • DRUG fospropofol disodium Subgroup 1 Approved Dose
  • DRUG fospropofol disodium Subgroup 2 Lower Dose
  • DRUG fospropofol disodium Subgroup 2 Approved Dose
  • DRUG fospropofol disodium Subgroup 3 Lower Dose

Trial Details

FieldValue
Enrollment Target 153 participants
Start Date 2010-04
Est. Completion 2011-06
Phase Phase 4

Sponsor

Eisai

287 total trials

What the Registry Record Tells You About NCT01127438

The ClinicalTrials.gov registry entry for NCT01127438 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which fospropofol disodium Subgroup 1 Lower Dose is the first listed.

NCT01127438 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01127438 about?

NCT01127438 is a clinical study titled "A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations". The purpose of this study is to evaluate the safety and efficacy of LUSEDRA (fospropofol disodium) and to determine whether a dose lower than currently approved can provide effective moderate sedation required to complete diagnostic or therapeutic procedures.

What is the current status of trial NCT01127438?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 153 participants. The study started on 2010-04. Estimated completion is 2011-06.

What interventions are being tested in trial NCT01127438?

The interventions under investigation include: fospropofol disodium Subgroup 1 Lower Dose (DRUG), fospropofol disodium Subgroup 1 Approved Dose (DRUG), fospropofol disodium Subgroup 2 Lower Dose (DRUG), fospropofol disodium Subgroup 2 Approved Dose (DRUG), fospropofol disodium Subgroup 3 Lower Dose (DRUG).

Who is sponsoring clinical trial NCT01127438?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.